Potency testing for the experimental Na-GST-1 hookworm vaccine

Expert Review of Vaccines

Volumn 9, Issue 10, 2010, Pages 1219-1230

  Jariwala, Amar R ^a   Oliveira, Luciana M ^b   Diemert, David J ^a,b   Keegan, Brian ^b   Plieskatt, Jordan L ^b   Periago, Maria V ^b,c   Bottazzi, Maria E ^b   Hotez, Peter J ^a,b   Bethony, Jeffrey M ^b  

^a Albert B Sabin Vaccine Institute   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

effective dose 50; hookworm vaccine; neglected tropical disease vaccine; potency assay; probit analysis

Indexed keywords

GLUTATHIONE TRANSFERASE; NA GST 1 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

BIOASSAY; CLINICAL FEATURE; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HOOKWORM INFECTION; HUMAN; NECATOR AMERICANUS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; TROPICAL DISEASE; VACCINATION; X RAY CRYSTALLOGRAPHY;

ANCYLOSTOMATOIDEA; ANIMALS; ANTIGENS, HELMINTH; CRICETINAE; DISEASE MODELS, ANIMAL; DOGS; DRUG DESIGN; GLUTATHIONE TRANSFERASE; HOOKWORM INFECTIONS; HUMANS; NECATOR AMERICANUS; VACCINES, SYNTHETIC;

EID: 77957952200     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.107     Document Type: Review

References (37)

1. Hotez PJ, Molyneux DH, Fenwick A et al. Control of neglected tropical diseases N. Engl. J. Med. 357(10), 1018-1027 (2007).
2. Arciniega JL. What s in a name? The meaning of the term potency , as applied to immunobiologicals for human use, and its implications for alternatives and validation. In: Progress in the Reduction, Refinement and Replacement of Animal Experimentation. Balls M, van Zeller A-M, Halder ME (Eds). Elsevier, Amsterdam, The Netherlands, 979-986 (2000).
3. Hendriksen C, Arciniega JL, Bruckner L et al. The consistency approach for the quality control of vaccines. Biologicals 36(1), 73-77 (2008).
4. Hotez PJ, Bethony J, Bottazzi ME et al. Hookworm: the great infection of mankind . PLoS Med. 2(3), 187 (2005).
5. Bethony J, Brooker S, Albonico M et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 367(9521), 1521-1532 (2006).
6. Brooker S, Bethony J, Hotez PJ. Human hookworm infection in the 21st Century. Adv. Parasitol. 58, 197-288 (2004). (Pubitemid 39643145)
7. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 299(16), 1937-1948 (2008).
8. Williamson AL, Brindley PJ, Knox DP et al. Digestive proteases of blood-feeding nematodes. Trends Parasitol. 19(9), 417-423 (2003).
9. Williamson AL, Lecchi P, Turk BE et al. A multi-enzyme cascade of hemoglobin proteolysis in the intestine of blood-feeding hookworms. J. Biol. Chem. 279(34), 35950-35957 (2004).
10. Ranjit N, Zhan B, Hamilton B et al. Proteolytic degradation of hemoglobin in the intestine of the human hookworm Necator americanus. J. Infect. Dis. 199(6), 904-912 (2009).
11. Hotez PJ, Ferris MT. The antipoverty vaccines. Vaccine 24(31-32), 5787-5799 (2006).
12. Zhan B, Liu S, Perally S et al. Biochemical characterization and vaccine potential of a heme-binding glutathione transferase from the adult hookworm Ancylostoma caninum. Infect. Immun. 73(10), 6903-6911 (2005).
13. Zhan B, Brophy P, Perally S et al. Molecular cloning, biochemical characterization and partial protective immunity of the heme-binding glutathione S-transferases from the human hookworm Necator americanus. Infect. Immun. 78(4), 1552-1563 (2010).
14. van Rossum AJ, Jefferies JR, Rijsewijk FAM et al. Binding of hematin by a new class of glutathione transferase from the blood-feeding parasitic nematode Haemonchus contortus. Infect. Immun. 72(5), 2780 (2004).
15. Schuller DJ, Liu Q, Kriksunov IA et al. Crystal structure of a new class of glutathione transferase from the model human hookworm nematode Heligmosomoides polygyrus. Proteins Struct. Funct. Bioinformat. 61, 1024-1031 (2005).
16. Asojo OA, Homma K, Sedlacek M et al. X-ray structures of Na-GST-1 and Na-GST-2 two glutathione S-transferase from the human hookworm Necator americanus. BMC Struct. Biol. 7, 42 (2007).
17. Xiao S, Zhan B, Xue J et al. The evaluation of recombinant hookworm antigens as vaccines in hamsters (Mesocricetus auratus) challenged with human hookworm, Necator americanus. Exp. Parasitol. 118(1), 32-40 (2008).
18. Hendriksen CFM. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement. Expert Rev. Vaccines 8(3), 313-322 (2009).
19. US Code of Federal Regulations, 21 CFR §600.3 (s). Department of Health and Human Services, US FDA, MD, USA (2009).
20. Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/ Biological Products. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland (1999).
21. Fujiwara RT, Zhan B, Mendez S et al. Reduction of worm fecundity and canine host blood loss mediates protection against hookworm infection elicited by vaccination with recombinant Ac-16. Clin. Vaccine Immunol. 14(3), 281 (2007).
22. Miller TA. Industrial development and field use of the canine hookworm vaccine. Adv. Parasitol. 16, 333-342 (1978).
23. Miller TA. Vaccination against the canine hookworm diseases. Adv. Parasitol. 9, 153-183 (1971).
24. Miller TA. Transfer of immunity to Ancylostoma caninum infection in pups by serum and lymphoid cells. Immunology 12(2), 231-241 (1967).
25. Xue J, Hui-Qing Q, Jun-Ming Y et al. Necator americanus: optimization of the golden hamster model for testing anthelmintic drugs. Exp. Parasitol. 111(4), 219-223 (2005).
26. Petricciani J, Egan W, Vicari G et al. Potency assays for therapeutic live whole cell cancer vaccines. Biologicals 35(2), 107-113 (2007).
27. Giersing BK, Dubovsky F, Saul A et al. Potency assay design for adjuvanted recombinant proteins as malaria vaccines. Vaccine 24(20), 4264-4270 (2006).
28. Finney DJ. Probit Analysis. University Press, Cambridge, UK (1971).
29. Voller A, Bartlett A, Bidwell D. Enzyme immunoassays with special reference to ELISA techniques. J. Clin. Pathol. 31(6), 507-520 (1978).
30. Voller A. The enzyme-linked immunosorbent assay (ELISA) (theory, technique and applications). Ric. Clin. Lab. 8(4), 289-298 (1978).
31. Crowther JR. The ELISA Guidebook. Humana Press, NJ, USA (2001).
32. Miura K, Orcutt AC, Muratova OV et al. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26(2), 193-200 (2007).
33. Plikaytis BD, Carlone GM. Statistical considerations for vaccine immunogenicity trials part 1: introduction and bioassay design and analysis. Vaccine 23(13), 1596-1605 (2005).
34. Quinn CP, Semenova VA, Elie CM et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg. Infect. Dis. 8(10), 1103-1110 (2002).
35. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin. Biochem. Rev. 29(Suppl. 1), S49-S52 (2008).
36. Buncher CR, Tsay JY. Statistics in the Pharmaceutical Industry. Chapman & Hall/ CRC, FL, USA (2006).
37. European Pharmacopoeia Commission. Statistical analysis of results of biological assays and tests. In: European Pharmacopoeia, 6th edition. Council of Europe, Strasbourg, France, 571-600 (2008).